LOIM
NVCR icon

Liberty One Investment Management’s NovoCure NVCR Stock Holding History

Liberty One Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-181
Closed -$2.83K – 172
2024
Q3 		$2.83K Sell
181
-1,077
-86% -$19.5K ﹤0.01% 163
2024
Q2 		$22K Buy
1,258
+14
+1% +$246 ﹤0.01% 158
2024
Q1 		$19.4K Buy
1,244
+52
+4% +$765 ﹤0.01% 168
2023
Q4 		$17.8K Buy
1,192
+1,032
+645% +$13.8K ﹤0.01% 145
2023
Q3 		$2.58K Buy
160
+38
+31% +$1.1K ﹤0.01% 160
2023
Q2 		$5.06K Hold
122
– – ﹤0.01% 164
2023
Q1 		$7.34K Buy
+122
New +$9.75K ﹤0.01% 152
2022
Q2 		– Sell
-15
Closed -$1K – 154
2022
Q1 		$1K Buy
+15
New +$1.1K ﹤0.01% 162

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Liberty One Investment Management's NVCR Position: Q4 2024 in Review

Liberty One Investment Management sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 181 shares — an estimated $2.83K sold.

Liberty One Investment Management first reported a position in NVCR in Q1 2022 and held it in 8 quarters. The position peaked at $22K in Q2 2024. 239 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Liberty One Investment Management reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Liberty One Investment Management sold 181 NovoCure shares in Q4 2024, an estimated $2.83K.
  • Liberty One Investment Management first reported a position in NovoCure in Q1 2022 and held it in 8 quarters.
  • Liberty One Investment Management's NovoCure position peaked at $22K in Q2 2024.
  • 239 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Liberty One Investment Management's 13F filing for Q4 2024, filed 16 Jan 2025.